Peter Fellner nominated to be elected to Biotie's Board of Directors

28-Sep-2009 - Finland

The Board of Directors proposes for the Extraordinary General Meeting on October 29, 2009 on the basis of the recommendation of the Board's Nomination and Remuneration Committee that the number of members of the Board of Directors would be eight (8) and that Dr. Peter Fellner would be elected as a new member of the Board of Directors for the term expiring at the end of the following Annual General Meeting.

Dr. Fellner, 65, currently serves as Chairman of Consort Medical Plc, Chairman of Vernalis Plc and Chairman of Astex Therapeutics Ltd. Previously he served as CEO of Celltech Group plc from 1990 to 2003, and then as its Chairman until 2004. Prior to this he was CEO of Roche UK from 1986 to 1990. He has also served as a director of several other public companies.

Dr. Fellner has given his consent to Board service. He is independent of the company and independent of significant shareholders of the company.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances